ABSTRACT
A study was made of the condition of 44 acromegalic patients at various time after gamma-beam therapy. It has shown that therapeutic efficacy depends on initial sizes of adenomas and the level of growth hormone as well as on the time of observation. At late terms after therapy normalization of the level of growth hormone was observed in 41% of patients, clinical improvement in 44%, the absence of and effect in 15%. Radiation therapy resulted in a decrease in some hypophyseal functions in some of the patients and postradiation hyperprolactinemia in 56% of patients with the normal level of prolactin before therapy. The main shortcoming of radiation therapy was the length of time, necessary for achieving a therapeutic effect.
Subject(s)
Acromegaly/radiotherapy , Adenoma/radiotherapy , Pituitary Neoplasms/radiotherapy , Acromegaly/etiology , Adenoma/complications , Female , Gamma Rays/therapeutic use , Humans , Male , Pituitary Gland, Anterior , Pituitary Neoplasms/complications , Remission Induction/methodsABSTRACT
A system of automated control Aspect-2 was developed for automation of gamma-beam therapy on units of the Rokus series. The system consists of the following hardware and software complexes: a complex of preirradiation preparation "Centrator-imitator"; a complex Accord for anatomotopographic data coding; a software complex and a gamma-therapeutic complex Rokus-AM. The Centrator-imitator and Rokus-AM complexes are fitted out with built-in microcomputers with specially developed systemic software. The Rokus-AM complex has automatic punch tape programmed control of 9 degrees of freedom of the gamma-unit and treatment table and ensures 5 modes of irradiation: positional, rotating, rotating-convergent, sectoral rotating-convergent and scanning.
Subject(s)
Radioisotope Teletherapy/instrumentation , Computer Systems , Gamma Rays , Humans , Software , USSRABSTRACT
The paper is concerned with the substantiation of multifractionated gamma-beam therapy and the results of the use of this regimen in radiotherapy of rectal cancer. The authors have proposed the following scheme of irradiation: a single focal dose of 2 Gy is delivered not once a day as in routine fractionation but twice a day with a 4-hour interval. A radiotherapeutic course has been divided into 3 stages of 5 days each with 5-day intervals in-between. The course total focal dose was 60 Gy, "time-dose-fractionation" factors--140, the equivalent total dose--83 Gy. Statistically significant improvement of immediate results and a decrease in the number and expression of radiation reactions were noted. Earlier (as compared to routine fractionation) appearance of a symptomatic effect and the reduction of a time-period of a radiotherapeutic course in bed-days by 30% were also noted.
Subject(s)
Radiotherapy Dosage , Rectal Neoplasms/radiotherapy , Adenocarcinoma/radiotherapy , Aged , Female , Humans , Male , Middle AgedSubject(s)
Adenocarcinoma/radiotherapy , Rectal Neoplasms/radiotherapy , Aged , Combined Modality Therapy , Female , Humans , Male , Middle AgedABSTRACT
The authors present a technique of concomitant radiotherapy of rectal cancer using 60Co movable sources of the Agat-B unit for contact irradiation. The paper is illustrated with the schemes of radiation sources in relation to tumors and pictures of dose fields formed by various radiation sources and positions as well as their time intervals in each position during a therapeutic session. The results of treatment of patients in the main group (47 persons) and in the control group when the patients received gamma-beam therapy only (45 persons) are also given in the paper. Two-year survival rates have shown significantly improved long-term results in the main group. The new method is recommended for practical use as a variant for extended indications to concomitant radiotherapy of rectal cancer and for improving its results.
Subject(s)
Brachytherapy/methods , Rectal Neoplasms/radiotherapy , Adult , Aged , Brachytherapy/instrumentation , Female , Follow-Up Studies , Gamma Rays , Humans , Male , Middle Aged , Radiation Injuries , Radiotherapy Dosage , Rectal Neoplasms/mortalitySubject(s)
Urinary Bladder Neoplasms/surgery , Aged , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Postoperative Care , Radiotherapy Dosage , Urinary Bladder/surgery , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/radiotherapyABSTRACT
The authors present the results of the use of dibunol in the form of liniment (1-10%) for the treatment of radiation cystitis and rectitis resulting from radiation therapy of small pelvic tumors, epidermitis and epithelitis that develop in the course of treatment of skin and lower lip tumors. A high efficacy of the drug in the therapy of radiation injury has been shown in 212 patients.
